Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation turns negative
Q1 FY2026 stock-based compensation was -$460K, compared with $1.37M a year earlier. Trailing-twelve-month stock-based compensation was $4.25M. Over 3 fiscal years it compounded at -7.5% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near -$460K or moves back toward the trailing-twelve-month quarterly average of $1.06M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 1.35M USD
- Year-over-year change
- -72.2%
- 4-year CAGR
- -8.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.35M | -72.2% |
| FY2024 | 2024-12-31 | 4.86M | +3.3% |
| FY2023 | 2023-12-31 | 4.71M | +175.6% |
| FY2022 | 2022-12-31 | 1.71M | -9.8% |
| FY2021 | 2021-12-31 | 1.89M | — |
Stock-Based Compensation vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's LTM Mar 2026 stock-based compensation of $4.25M is the 9th largest of the 11 companies compared; the peer median is $10.29M.
- Its year-over-year change of -13.9% is the 7th highest of 11, against a peer median of -3.6%.
- Over three fiscal years its annual growth of -7.5% compares with a peer median of +23.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $49.18M | +10.5% | +43.7% | 22.6% | |
| LTM Mar 2026 | $38.79M | +1.8% | +32.7% | 179.5% | |
| LTM Mar 2026 | $25.38M | +66.4% | — | — | |
| LTM Jun 2026 | $19.89M | -153.0% | +30.1% | 11.7% | |
| LTM Mar 2026 | $12.55M | -55.6% | -11.3% | 8.0% | |
| LTM Mar 2026 | $10.93M | +20.5% | +16.2% | — | |
| LTM Mar 2026 | $9.66M | +26.4% | +15.9% | 19.5% | |
| LTM Mar 2026 | $6.93M | -9.1% | +16.8% | 1385.0% | |
| LTM Mar 2026 | $4.25M | -13.9% | -7.5% | — | |
| LTM Mar 2026 | $2.15M | -27.0% | +57.6% | — | |
| LTM Mar 2026 | $1.52M | -69.5% | — | — | |
| Peer median (excluding NVCT) | $10.29M | -3.6% | +23.5% | 21.1% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.89M | 1.71M | 4.71M | 4.86M | 1.35M |
| Change in Working Capital | 1.49M | 3.82M | 1.74M | 1.9M | 4.4M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 1.85M | (139K) | (273K) | 3.78M |
| Other Working Capital | 1.49M | 1.97M | 1.88M | 2.17M | 625K |
| Other Non-Cash Items | 0 | 0 | (139K) | 0 | 4.68M |
| Operating Cash Flow | (9.5M) | (13.56M) | (15.95M) | (12.25M) | (16.01M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 15.25M | 31.88M | 5.29M | 12.04M | 29.11M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (4.07M) | 9.8M | (382K) | 0 |
| Financing Cash Flow | 15.25M | 27.81M | 15.09M | 11.65M | 29.11M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.74M | 14.25M | (867K) | (593K) | 13.1M |
| Free Cash Flow | (9.5M) | (13.56M) | (15.95M) | (12.25M) | (16.01M) |
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.